Page last updated: 2024-12-10
ac 915
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
AC 915: binds sigma(1) opioid receptors; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5236783 |
| CHEMBL ID | 53649 |
| SCHEMBL ID | 3230649 |
| MeSH ID | M0357520 |
Synonyms (24)
| Synonym |
|---|
| 6692-13-3 |
| LOPAC0_000016 |
| lopac-a-3595 |
| NCGC00015052-01 , |
| ac 915 oxalate |
| NCGC00162044-01 |
| 2-(pyrrolidin-1-yl)ethyl 2-(3,4-dichlorophenyl)acetate |
| (3,4-dichloro-phenyl)-acetic acid 2-pyrrolidin-1-yl-ethyl ester |
| bdbm50084012 |
| CHEMBL53649 , |
| 2-pyrrolidin-1-ylethyl 2-(3,4-dichlorophenyl)acetate |
| CCG-204112 |
| NCGC00015052-02 |
| 259729-84-5 |
| ac-915 |
| unii-zt6k8rig8n |
| ac 915 |
| benzeneacetic acid, 3,4-dichloro-, 2-(1-pyrrolidinyl)ethyl ester |
| zt6k8rig8n , |
| SCHEMBL3230649 |
| DTXSID60985586 |
| 2-(pyrrolidin-1-yl)ethyl (3,4-dichlorophenyl)acetate |
| Q27295881 |
| AKOS040747747 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (4)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 31.6228 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 17.0390 | 0.0010 | 6.0009 | 35.4813 | AID943; AID944 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.0049 | 0.0000 | 0.4901 | 10.0000 | AID203683 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| lipid transport | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| nervous system development | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| G protein-coupled opioid receptor signaling pathway | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| regulation of neuron apoptotic process | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| protein homotrimerization | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Molecular Functions (2)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein-coupled opioid receptor activity | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| protein binding | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (13)
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID256864 | Percentage inhibition of rat C6 glioma cell proliferation mediated by sigma 1 receptor at 50 uM | 2005 | Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26 | Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the sigma(1) receptor. |
| AID232239 | Selectivity and expressed as ratio of sigma 2/sigma 1 | 2000 | Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1 | A sigma-1 receptor selective analogue of BD1008. A potential substitute for (+)-opioids in sigma receptor binding assays. |
| AID203683 | Compound was tested for its binding affinity against sigma 1 opioid receptor using 3[H](+)-pentazocine as radioligand | 2000 | Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1 | A sigma-1 receptor selective analogue of BD1008. A potential substitute for (+)-opioids in sigma receptor binding assays. |
| AID203827 | Binding affinity against sigma 2 opioid receptor using 3[H]-DTG in the presence of dextrallorphan as radioligand | 2000 | Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1 | A sigma-1 receptor selective analogue of BD1008. A potential substitute for (+)-opioids in sigma receptor binding assays. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 37.48
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.48) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||